Compare ZVIA & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZVIA | NVCT |
|---|---|---|
| Founded | 2007 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.4M | 197.0M |
| IPO Year | 2021 | 2022 |
| Metric | ZVIA | NVCT |
|---|---|---|
| Price | $2.55 | $7.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $4.89 | ★ $15.33 |
| AVG Volume (30 Days) | ★ 816.1K | 94.5K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $162,849,000.00 | N/A |
| Revenue This Year | $7.60 | N/A |
| Revenue Next Year | $6.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.17 | N/A |
| 52 Week Low | $1.88 | $4.44 |
| 52 Week High | $4.99 | $11.52 |
| Indicator | ZVIA | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 46.91 | 70.05 |
| Support Level | $2.54 | $6.47 |
| Resistance Level | $2.71 | $7.77 |
| Average True Range (ATR) | 0.09 | 0.40 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 22.22 | 89.75 |
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.